Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | NAPEPLD | Q6IQ20 | 6/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | SMO | Q99835 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686896 | 0.81 | IDH1 (0.42) | IDH1PIK3CAALDH1A1 | |
| SCHEMBL19686424 | 0.78 | CHRM3 (0.41) | IDH1PIK3CAALDH1A1 | |
| SCHEMBL21143734 | 0.77 | PIK3CA (0.42) | RAF1PIK3CAPIK3CBNAPEPLDCNR2 | |
| SCHEMBL20153240 | 0.77 | NAPEPLD (0.33) | RAF1IDH1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21143807 | 0.77 | KDM1A (0.36) | RAF1PIK3CAPIK3CBNAPEPLDCNR2 | |
| SCHEMBL21144008 | 0.75 | IDH1 (0.43) | IDH1CD38 | |
| SCHEMBL19686895 | 0.74 | ATR (0.33) | RAF1PIK3CDPIK3CAPIK3CBCREBBP | |
| SCHEMBL21144111 | 0.73 | IDH1 (0.39) | IDH1KDM1ACD38 | |
| SCHEMBL19686482 | 0.71 | KDM4E (0.43) | RAF1IDH1PIK3CACREBBPALDH1A1 | |
| SCHEMBL19687051 | 0.71 | IDH1 (0.43) | IDH1PIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3571193-B1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-11-21 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| WO-2018136917-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | RAF1 470/4885IDH1 3017/4885PIK3CD 897/4885 |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | RAF1 765/4885IDH1 2868/4885PIK3CD 1440/4885 |
| US-10717728-B2 | Potassium channel modulators | KCNJ2, KCNQ2, KCNJ1 | RAF1 641/4885IDH1 2691/4885PIK3CD 986/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | RAF1 470/4885IDH1 3017/4885PIK3CD 897/4885 |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | RAF1 765/4885IDH1 2868/4885PIK3CD 1440/4885 |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | RAF1 765/4885IDH1 2868/4885PIK3CD 1440/4885 |
| US-10351553-B2 | Potassium channel modulators | KCNN2, KCNN1, KCNN3 | RAF1 521/4885IDH1 3070/4885PIK3CD 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.